OurIgGglycanlibraryisamixtureofnonfucosylatedandfucosylated,bi-antennaryglycanstandardswithvariablesialylationreleasedfromhumanIgGantibodyglycoprotein.Theyareavailableunlabeledandlabeledwithavarietyoftags.
WealsosupplyanIgGglycoproteinstandardforuseduringglycanreleaseandlabeling.
“Glycosylationcansignificantlyaffecttheinvivosafetyandefficacyprofilesoftherapeuticrecombinantmonoclonalantibodies(rMAbs).Inparticular,glycanscanhaveamarkedinfluenceonIgGFceffectorfunctionsandchangesinantibodyglycosylationareamajorcauseofbatch-to-batchvariABIlityduringproduction.Forthesereasons,itisessentialtomeasureandcontrolantibodyglycosylationaccuratelyandreliably.”ThisintroductionwascopiedfromDr.DarylFernandes’articleDemonstratingComparabilityofAntibodyGlycosylationduringBiomanufacturing
Sources: TheIgGglycanlibraryintheseproductsarereleasedfromanIgGstandardthatispurifiedfromhumanserum.IgGexistsinavarietyofglycoformscontainingbi-antennaryoligosaccharideswithvariablesialylation.
Form: Dry.Driedbycentrifugalevaporationfromanaqueoussolution.
Amountsupplied
CLIBN-IGG-01 25µgs–unlabeled
CAB-IGG-01 200pmol–2-ABlabeled
CAPTS-IGG-01 10pmol–APTSlabeled
CPROC-IGG-02 50pmol–procainamidelabeled
CPM-IGG-01 20MSruns–permethylated
CPM-C13-IGG-01 20MSruns–permethylatedwithheavy(13C)MeI
PermethylatedIgGglycanstandardsforMSanalysis
Massspectrometry(MS)isausefultoolindeterminingthemolecularweightsbutthesensitivitycanbelowespeciallywheretherearemanydifferentstructures.Carbohydratesoftencontaincarboxy,amino,sulphate,andphosphategroups.Thenatureandthepositionofthesegroupsontheresidue,aswellasthepositionofthisresiduewithintheglycanmaybedifficulttodetermine.Permethylationofglycansconvertshydrogengroupstomethylgroupswhichrenderstheglycanshydrophobic;theconversionstabilisessialicacidsandcanincreasesignalintensityinmassmeasurements.
WenowofferaLudgerTagapermethylatedIgGglycanlibrarytouseasasystemsuitabilitystandardduringMSanalysis.WealsoofferaC13versionwhichcanbeusedasaninternalstandardinthesameMALDIchipspotasyourC12-labelledpermethylatedglycans.
MassspectrumofpermethylatedIgGN-GlycansstandardreleasedfromHumanIgGantibodybyN-Modehydrazinolysis.AnalysisperformedonBrukerAutoflexMALDI-Ion
Purity: >90%pureasassessedbyacombinationof1H-NMRandHPLC,andCE
Storage: -20˚Cbothbeforeandafterdissolution.Theproductsarestableforatleast5yearsassupplied.
ViewCertificateofStabilty
Shipping: Theproductcanbeshippedatambientwhendry.Afterdissolution,shipondryice.
Handling: Allowtheunopenedvialtoreachambienttemperatureandtapunopenedonasolidsurfacetoensurethatmostofthelyophilizedmaterialisatthebottomofthevial.Gentlyremovethecap,addthedesiredvolumeofreconstitutionmedium,re-capandmixthoroughlytobringalltheoligosaccharideintosolution.Formaximalrecoveryofoligosaccharide,ensurethatthecapliningisalsorinsedandcentrifugethereconstitutedvialbrieflybeforeuse.Ensurethatanyglass,plasticwareorsolventsusedarefreeofglycosidasesandenvironmentalcarbohydrates.MinimiseexposuretoelevatedtemperaturesorextremesofpH.HightemperaturesandlowpHwillcausedesialylation.HighpHwillcauseepimerisationofthereducingterminusGlcNAc.
Safety: Thisproductisnon-hazardousandhasbeenpurifiedfromnaturalsourcescertifiedtobefreeofallhazardousmaterialincludingpathogenicBIOLOGicalagents.
DownloadNon-hazardousMSDS
References
BeyerB,SchusterM,JungbauerA,LinggN.MicroheterogeneityofRecombinantAntibodies:AnalyticsandFunctionalImpact.BiotechnolJ.2018Jan;13(1).doi:10.1002/biot.201700476.Epub2017Sep25.Review.
ShaS,AgarabiC,BrorsonK,LeeDY,YoonS.N-GlycosylationDesignandControlofTherapeuticMonoclonalAntibodies.TrendsBiotechnol.2016Oct;34(10):835-846.doi:10.1016/j.tibtech.2016.02.013.Epub2016Mar22.Review
LiuL.AntibodyglycosylationanditsimpactonthepharmacokineticsandpharmacodynamicsofmonoclonalantibodiesandFc-fusionproteins.JPharmSci.2015Jun;104(6):1866-1884.doi:10.1002/jps.24444.Epub2015Apr14.
JefferisR.Recombinantantibodytherapeutics:theimpactofglycosylationonmechanismsofaction.TrendsPharmacolSci.2009Jul;30(7):356-62.doi:10.1016/j.tips.2009.04.007.Epub2009Jun22.Review.
JefferisR.Glycosylationofrecombinantantibodytherapeutics.BiotechnolProg21:pp11-16,2005
FernandesD.DemonstratingComparabilityofAntibodyGlycosylationduringBiomanufacturing.EuropeanBiopharmaceuticalReview.Summer2005.pp106-110
